News | November 22, 2022
Merck to acquire Imago BioSciences for $1.35 bn
Acquisition expands Merck’s growing hematology portfolio
Acquisition expands Merck’s growing hematology portfolio
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
The move will add new global talent to Cytel’s Strategic Consulting group
This win is on the back of a prestigious order from Reliance Life Sciences
Construction is now underway with the facility scheduled to be operational by 2025
Subscribe To Our Newsletter & Stay Updated
